Short Interest in Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Increases By ∞

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) was the target of a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 134,468 shares, an increase of ∞ from the July 30th total of 0 shares. Based on an average trading volume of 473,636 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are short sold.

Latigo Biotherapeutics Stock Performance

NASDAQ:LTGO opened at $24.23 on Monday. Latigo Biotherapeutics has a twelve month low of $17.22 and a twelve month high of $25.93.

Insider Transactions at Latigo Biotherapeutics

In other Latigo Biotherapeutics news, Director James B. Tananbaum bought 140,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the purchase, the director directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the insider directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Latigo Biotherapeutics to a “hold” rating in a research note on Saturday, August 15th.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.